Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.32 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27538550 | 0.87 | ADORA2A (0.44) | CCNA2CDK2CCNA1CDK5DYRK1A | |
| SCHEMBL1496411 | 0.81 | CDK2 (0.46) | CCNA2CDK2CCNA1CDK5DYRK1A | |
| SCHEMBL21311363 | 0.81 | KDM4E (0.42) | CDK2ADORA2AADORA2BADORA1PIK3CA | |
| SCHEMBL28704049 | 0.79 | FGFR1 (0.32) | FGFR1FGFR4 | |
| SCHEMBL111660 | 0.77 | KDM4E (0.36) | CCNA2CDK2CCNA1CDK5DYRK1A | |
| SCHEMBL5839419 | 0.75 | FGFR1 (0.40) | CDK2ADORA2AADORA1FGFR1FGFR4 | |
| SCHEMBL30148781 | 0.74 | CDK1 (0.41) | CCNA2CDK2CCNA1CDK5DYRK1A | |
| SCHEMBL1913380 | 0.74 | CDK1 (0.41) | CCNA2CDK2CCNA1CDK5DYRK1A | |
| SCHEMBL4187054 | 0.74 | DHFR (0.33) | — | |
| SCHEMBL29141665 | 0.72 | ADORA2A (0.41) | CDK2ADORA2AADORA2BADORA1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| EP-2029145-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | Novartis Ag (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| CN-1298719-C | Purine derivatives, process for their preparation and pharmaceutical compositions containing them | EIWENTIS MEDICAMENT (FR) | 2007-02-07 | — | — | CN | disclosed |
| CN-1361780-A | Purine derivatives, preparation method and pharmaceutical compositions containing same | EIWENTIS MEDICAMENT (FR) | 2002-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CCNA2 213/4885CDK2 5/4885CCNA1 357/4885 |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | PRKDC, TK2, PNKP | CCNA2 213/4885CDK2 5/4885CCNA1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.